The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1474
Rifaximin (Xifaxan) for Irritable Bowel Syndrome with Diarrhea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Rifaximin (Xifaxan – Salix), a minimally absorbed oral antibiotic approved previously to treat travelers' diarrhea and to reduce the risk of recurrent hepatic encephalopathy, has now been approved by the FDA for treatment of irritable bowel syndrome with diarrhea (IBS-D). Eluxadoline (Viberzi – Actavis), a mu-opioid receptor agonist, was also recently approved for IBS-D and will be reviewed in a future issue.

SOME TREATMENTS FOR IBS — Symptoms of IBS can include abdominal pain, bloating, flatulence, diarrhea, and constipation. Extra-intestinal complaints are also common. IBS is subtyped, according to the predominant bowel symptom, as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), mixed-type (IBS-M), or unclassified (IBS-U). The goal of treatment is symptom control; dietary modifications may help improve symptoms of all subtypes of IBS.

For patients with ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Rifaximin (Xifaxan) for Irritable Bowel Syndrome with Diarrhea
Article code: 1474b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian